Radiopharmaceuticals
Page 1 • 3 itemsUnlock global radiopharmaceutical market insights. NovaPharmaNews delivers critical intelligence for investors, BD, and analysts on nuclear medicine innovation.
Sprout Pharmaceuticals Addyi (Flibanserin) Maker Named Top 10 Most Influential Health Company by TIME 2026
Sprout Pharmaceuticals, maker of Addyi (flibanserin), joins TIME's 10 most influential health companies of 2026 following FDA approval expansion and growth.
C-Ray Therapeutics Receives FDA Acceptance for Copper-64 Drug Master File, Advancing Radiopharmaceutical Development
C-Ray Therapeutics' Copper-64 Drug Master File receives FDA acceptance, enabling global radiopharmaceutical developers to reference DMF No. 43568 for submissions.
Aclaris Therapeutics ATI-052 Phase 1a Trial Results and ATI-2138 Lead Indication Update Set for April 28, 2026
Aclaris Therapeutics announces Phase 1a trial results for anti-TSLP/IL-4R bispecific antibody ATI-052 and lead indication selection for ITK/JAK3 inhibitor ATI-2138.